The historical rank and industry rank for Colinz Laboratories's OCF Margin % or its related term are showing as below:
BOM:531210'
s OCF Margin % Range Over the Past 10 Years
Min: -22.27 Med: 6.17 Max: 35.04
Current: -24.89
During the past 13 years, the highest OCF Margin % of Colinz Laboratories was 35.04%. The lowest was -22.27%. And the median was 6.17%.
BOM:531210's OCF Margin % is ranked worse than 87.9% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs BOM:531210: -24.89
Colinz Laboratories OCF Margin % Related Terms
Colinz Laboratories OCF Margin % Historical Data
* Premium members only.
The historical data trend for Colinz Laboratories's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Colinz Laboratories's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Colinz Laboratories OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Colinz Laboratories's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Colinz Laboratories's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Colinz Laboratories (BOM:531210) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Colinz Laboratories and its competitors. According to the industry distribution chart, Colinz Laboratories ranks #843 out of 959 companies in the Drug Manufacturers industry, placing it in the top 87.9%.
Is Colinz Laboratories' OCF Margin % too high?
Colinz Laboratories' current OCF Margin % is 0.00%. Based on the distribution chart, Colinz Laboratories ranks #843 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Colinz Laboratories has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Colinz Laboratories ranks #843 out of 959 companies for OCF Margin %. This places Colinz Laboratories in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Colinz Laboratories and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Colinz Laboratories's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹41.74, compared to a current price of ₹71.96 — trading 72.4% above its estimated fair value. The current OCF Margin % is 0.00%. Colinz Laboratories' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Colinz Laboratories (BOM:531210) Overvalued in 2026?
Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued.
The current stock price of ₹71.96 is trading 72.4% above its estimated GF Value™ of ₹41.74.
GuruFocus considers Colinz Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:531210:
OCF Margin %: 0.00%
GF Value™: ₹41.74 vs. price of ₹71.96 (72.4% above fair value)
No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
68GF Score
Get the complete analysis for BOM:531210
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531210 has been successfully added to your 
